VAISHALI.NS Stock Analysis
VA
Avoid
Based on Eyestock quantitative analysis, VAISHALI.NS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
Vaishali Pharma Ltd. is a healthcare company, which engages in the marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2017-08-22. The firm is engaged in dealing in pharmaceutical ingredient, pharmaceutical formulations, surgical products, herbal and nutraceutical products, veterinary supplements operating in domestic and export market. In domestic markets, it is engaged in contract manufacturing and trading of active pharmaceuticals ingredient's (APIs) and supply of API's for export captive consumption. In export markets, it is engaged in manufacturing and export of pharmaceutical formulations; manufacturing and export of surgical products; manufacturing and export of veterinary products; and manufacturing and export of herbal and nutraceuticals products. Its product categories include API, formulation brands, formulations, herbal, nutraceuticals, oncology, surgical and veterinary, among others. The firm markets approximately 400 products in domestic and APIs has a product portfolio of more than 1,000 products for the overseas market.